Cell Therapeutics vor Tounaround?
18.03.11 16:57
#801
DerWahrsager
News vom 13.3.
http://hotpennystocksonline.com/?p=369
das war vielen im Amiland noch gar nicht bekannt, viele sprechen von einem Hype innerhalb von wenigen Tagen über einem Dollar, dass viele calls gekauft wurden und und und, einige schreiben 2 Dollar oder mehr im Amiboard, nun die news werden die Richtung bestimmen immer locker bleiben...
mm
das war vielen im Amiland noch gar nicht bekannt, viele sprechen von einem Hype innerhalb von wenigen Tagen über einem Dollar, dass viele calls gekauft wurden und und und, einige schreiben 2 Dollar oder mehr im Amiboard, nun die news werden die Richtung bestimmen immer locker bleiben...
mm
21.03.11 09:18
#803
xnomis
CTIC Initiates Pixantrone PIX-R Pivot Trial - NEWS
Cell Therapeutics Initiates Pixantrone PIX-R Pivotal Trial for Treatment of Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
prnewswire
*
Companies:
o Cell Therapeutics, Inc.
Related Quotes
Symbol Price Change §
CTIC 0.44 0.00§
Chart for Cell Therapeutics, Inc.
{"s" : "ctic","k" : "a00,a50,b00,b60,c10,g00,h00,l10,p20,t10,v00","o" : "","j" : ""}
Press Release Source: Cell Therapeutics, Inc. On Monday March 21, 2011, 2:30 am EDT
SEATTLE, March 21, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) today announced that it has initiated its randomized pivotal trial of pixantrone for the treatment of relapsed/refractory diffuse large B-cell lymphoma ("DLBCL"). The clinical trial is now open to patient enrollment. The trial, referred to as the PIX-R or PIX 306 trial, will compare a combination of pixantrone plus rituximab to a combination of gemcitabine plus rituximab in patients with relapsed or refractory DLBCL who have received one to three prior lines of therapy. The PIX-R trial utilizes progression free survival ("PFS") and overall survival ("OS") as co-primary endpoints of the study. The PIX-R trial is targeting to enroll approximately 350 patients over 18 months and will include patients who have failed at least one line of previous therapy and patients who are not candidates for myeloablative chemotherapy and stem cell transplant.
"We are pleased to open enrollment for this study and have been in communication with leading cancer clinical sites that are enthusiastic about participating in the study largely based on the positive results of our previous study, PIX 301, in relapsed/refractory aggressive non-Hodgkin's lymphoma patients," said Jack W. Singer, M.D., Chief Medical Officer of CTI. "There is an unmet medical need in this patient group, and the lack of any FDA approved drug for these patients should generate strong interest in the trial from both the patients and physicians."
For more information on the PIX-R trial, investigators and patients can visit www.pixrtrial.com. CTI expects the PIX-R trial to be posted to www.clinicaltrials.gov in the near future. CTI expects to have 60 sites open for enrollment by the end of April 2011.
The PIX-R trial may serve as either a post-marketing commitment trial or as a follow-on pivotal trial depending on the outcome of a formal appeal that CTI submitted to the Food & Drug Administration's (the "FDA") Office of New Drugs in the FDA's Center for Drug Evaluation and Research in December 2010 regarding its 2010 decision about CTI's new drug application (the "NDA") for pixantrone. The NDA for pixantrone was based on the results of the PIX 301 trial, a randomized trial comparing pixantrone as monotherapy to a choice of standard single-agent chemotherapy in relapsed/refractory aggressive non-Hodgkin's lymphoma ("NHL") patients. CTI expects a decision regarding its appeal in the second quarter of 2011.
PIX-R TRIAL Design
The PIX-R trial is designed to be a randomized, multicenter study comparing pixantrone plus rituximab to gemcitabine plus rituximab in patients with relapsed or refractory DLBCL or DLBCL transformed from follicular lymphoma who have received one to three prior lines of therapy, including CHOP-R or an equivalent regimen. The patients to be enrolled in the PIX-R trial cannot be eligible for high-dose (myeloablative) chemotherapy and stem cell transplant, but patients who relapse after such a procedure are eligible. The co-primary endpoints for the PIX-R trial are PFS and OS with secondary endpoints including overall response rate ("ORR") (ORR equals complete responses plus partial responses), complete response rate and safety. CTI is targeting to enroll 350 patients over 18 months in the PIX-R trial.
About Pixantrone
Pixantrone is a novel aza-anthracenedione that has distinct structural and physio-chemical properties that make its anti-tumor activity unique in this class of agents. Similar to anthracyclines, pixantrone inhibits Topo-isomerase II, but unlike anthracyclines, rather than intercalation with DNA, pixantrone alkylates DNA and forms stable DNA adducts with particular specificity for CpG rich, hyper-methylated sites. These structural differences resulted in significantly enhanced anti-lymphoma activity compared to doxorubicin in preclinical models. In addition, the structural motifs on anthracycline-like agents that are responsible for the generation of oxygen free radicals and the formation of toxic drug-metal complexes have also been modified in pixantrone to prevent the binding of iron and perpetuation of superoxide production--both of which are the putative mechanism for anthracycline induced acute cardiotoxicity. These novel pharmacologic differences may allow re-introduction of anthracycline-like potency in the treatment of relapsed/refractory diffuse large lymphoma without unacceptable rates of cardiotoxicity.
prnewswire
*
Companies:
o Cell Therapeutics, Inc.
Related Quotes
Symbol Price Change §
CTIC 0.44 0.00§
Chart for Cell Therapeutics, Inc.
{"s" : "ctic","k" : "a00,a50,b00,b60,c10,g00,h00,l10,p20,t10,v00","o" : "","j" : ""}
Press Release Source: Cell Therapeutics, Inc. On Monday March 21, 2011, 2:30 am EDT
SEATTLE, March 21, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) today announced that it has initiated its randomized pivotal trial of pixantrone for the treatment of relapsed/refractory diffuse large B-cell lymphoma ("DLBCL"). The clinical trial is now open to patient enrollment. The trial, referred to as the PIX-R or PIX 306 trial, will compare a combination of pixantrone plus rituximab to a combination of gemcitabine plus rituximab in patients with relapsed or refractory DLBCL who have received one to three prior lines of therapy. The PIX-R trial utilizes progression free survival ("PFS") and overall survival ("OS") as co-primary endpoints of the study. The PIX-R trial is targeting to enroll approximately 350 patients over 18 months and will include patients who have failed at least one line of previous therapy and patients who are not candidates for myeloablative chemotherapy and stem cell transplant.
"We are pleased to open enrollment for this study and have been in communication with leading cancer clinical sites that are enthusiastic about participating in the study largely based on the positive results of our previous study, PIX 301, in relapsed/refractory aggressive non-Hodgkin's lymphoma patients," said Jack W. Singer, M.D., Chief Medical Officer of CTI. "There is an unmet medical need in this patient group, and the lack of any FDA approved drug for these patients should generate strong interest in the trial from both the patients and physicians."
For more information on the PIX-R trial, investigators and patients can visit www.pixrtrial.com. CTI expects the PIX-R trial to be posted to www.clinicaltrials.gov in the near future. CTI expects to have 60 sites open for enrollment by the end of April 2011.
The PIX-R trial may serve as either a post-marketing commitment trial or as a follow-on pivotal trial depending on the outcome of a formal appeal that CTI submitted to the Food & Drug Administration's (the "FDA") Office of New Drugs in the FDA's Center for Drug Evaluation and Research in December 2010 regarding its 2010 decision about CTI's new drug application (the "NDA") for pixantrone. The NDA for pixantrone was based on the results of the PIX 301 trial, a randomized trial comparing pixantrone as monotherapy to a choice of standard single-agent chemotherapy in relapsed/refractory aggressive non-Hodgkin's lymphoma ("NHL") patients. CTI expects a decision regarding its appeal in the second quarter of 2011.
PIX-R TRIAL Design
The PIX-R trial is designed to be a randomized, multicenter study comparing pixantrone plus rituximab to gemcitabine plus rituximab in patients with relapsed or refractory DLBCL or DLBCL transformed from follicular lymphoma who have received one to three prior lines of therapy, including CHOP-R or an equivalent regimen. The patients to be enrolled in the PIX-R trial cannot be eligible for high-dose (myeloablative) chemotherapy and stem cell transplant, but patients who relapse after such a procedure are eligible. The co-primary endpoints for the PIX-R trial are PFS and OS with secondary endpoints including overall response rate ("ORR") (ORR equals complete responses plus partial responses), complete response rate and safety. CTI is targeting to enroll 350 patients over 18 months in the PIX-R trial.
About Pixantrone
Pixantrone is a novel aza-anthracenedione that has distinct structural and physio-chemical properties that make its anti-tumor activity unique in this class of agents. Similar to anthracyclines, pixantrone inhibits Topo-isomerase II, but unlike anthracyclines, rather than intercalation with DNA, pixantrone alkylates DNA and forms stable DNA adducts with particular specificity for CpG rich, hyper-methylated sites. These structural differences resulted in significantly enhanced anti-lymphoma activity compared to doxorubicin in preclinical models. In addition, the structural motifs on anthracycline-like agents that are responsible for the generation of oxygen free radicals and the formation of toxic drug-metal complexes have also been modified in pixantrone to prevent the binding of iron and perpetuation of superoxide production--both of which are the putative mechanism for anthracycline induced acute cardiotoxicity. These novel pharmacologic differences may allow re-introduction of anthracycline-like potency in the treatment of relapsed/refractory diffuse large lymphoma without unacceptable rates of cardiotoxicity.
04.04.11 22:51
#807
Heron
Substitution-of-Pixantrone
http://finance.yahoo.com/news/...-prnews-2548321071.html?x=0&.v=1
17.05.11 16:44
#808
tomek201076
Habe ich was verpasst???
Habe festgestellt dass das Papier seit gestern nicht mehr gehandelt wird.
Kann jemand was dazu schreiben?
Für jede Info bin ich dankbar...
Kann jemand was dazu schreiben?
Für jede Info bin ich dankbar...
18.05.11 07:06
#809
Jing
Ja - rechtzeitig zu verkaufen,
Reverse Split 10:1, meist gehts danach froehlich weiter nach Sueden.
Scheint z.Z. bei den Billigheimern der letzte Schrei zu sein um nicht
aus dem Index zu fliegen.
Scheint z.Z. bei den Billigheimern der letzte Schrei zu sein um nicht
aus dem Index zu fliegen.
18.05.11 07:27
#810
tomek201076
Vielen Dank....
und jetzt???
... muss ich also meine Papiere noch nicht abschreiben?
Haben die noch irgend einen Wert?
Werden diese wieder gelistet?
Habe nur was von Bezugsrechten mit verhältnis 1:6 gelesen.
... muss ich also meine Papiere noch nicht abschreiben?
Haben die noch irgend einen Wert?
Werden diese wieder gelistet?
Habe nur was von Bezugsrechten mit verhältnis 1:6 gelesen.
18.05.11 07:42
#811
wilbär
Moin tomek,
Diese RS Spielchen sind bei US Bios leider gängige Praxis.
Schau Dir einfach mal Genta an,im schlechtesten Fall könnte es hier ähnlich laufen.
Gruß Wilbär.
Schau Dir einfach mal Genta an,im schlechtesten Fall könnte es hier ähnlich laufen.
Gruß Wilbär.
25.10.11 21:11
#812
DerWahrsager
Das sieht doch schon wieder
etwas besser aus, trotz schlechter Zahlen...
06.12.11 20:07
#813
Biggemann
Sollte das der Grund für den Kursanstieg sein?
http://investors.celltherapeutics.com/...&cat=news&id=1636458
06.12.11 20:37
#814
Biggemann
Geht wirklich gut ab.
Jetzt 20% im Plus.Bin mal gespannt ob die 1,50$ noch heute noch fällt.
Auf jeden fall sehr viel Platz nach oben.
Auf jeden fall sehr viel Platz nach oben.
07.12.11 07:31
#815
tomek201076
nicht ganz,
aber die 1,30$ sind auch nicht schlecht...
Ich hoffe wir gehen heute über 1,50$
Ich hoffe wir gehen heute über 1,50$
07.12.11 21:47
#817
tomek201076
13 min haben wir noch.
Vielleicht schließen wir noch mit 5 mon. hoch. :-)
09.12.11 20:31
#819
Biggemann
Etwas seltsam heute hier.
Erst ca.-20%,jetzt noch etwa 12%.
Gerade erst ein Kauf von ca.118000$.
Irgend etwas ist da im Busch.
Werde mich auf jedenfall von dem Kursrücksetzter nicht aus der Ruhe bringen lassen.
Gerade erst ein Kauf von ca.118000$.
Irgend etwas ist da im Busch.
Werde mich auf jedenfall von dem Kursrücksetzter nicht aus der Ruhe bringen lassen.
20.01.12 20:36
#821
Biggemann
Netter Anstieg bis jetzt.
Stellt sich mir wieder einmal die Frage,wird es jetzt mal ernst hier?
Wir haben ja mal wieder Freitag.Normal würde ich erst mal wieder an einen Zock denken.
Aber vielleicht gehts ja hier mal richtig aufwärts.
Bin ja lange genug dabei.
lg
Wir haben ja mal wieder Freitag.Normal würde ich erst mal wieder an einen Zock denken.
Aber vielleicht gehts ja hier mal richtig aufwärts.
Bin ja lange genug dabei.
lg
20.01.12 22:08
#822
Biggemann
Sieht nicht unbedingt nach Zock aus.
Bei dem heutigen Volumen und der Aussicht auf Zulassung( erst einmal EU),
habe ich endlich mal wieder Hoffnung.
Wenn es denn eine Zulassung geben sollte(keine Ahnung)wäre es die erste dieser Art.
Und die Aktie geht ab wie sonst was.
Also,Chance 50:50
LF
habe ich endlich mal wieder Hoffnung.
Wenn es denn eine Zulassung geben sollte(keine Ahnung)wäre es die erste dieser Art.
Und die Aktie geht ab wie sonst was.
Also,Chance 50:50
LF
23.01.12 16:16
#823
Biggemann
Auch heute wieder
ein netter Anstieg,ca.13%nach einer kappen Stunde Handel.
23.01.12 22:07
#824
Biggemann
So kann es gerne
noch 3 Wochen weitergehen.
Und dann sollte sich sich die Aktie aus dem 1stelligem Bereich verabschieden.
Aber nur wenn alles gut läuft.
Chance:50:50
LG
Und dann sollte sich sich die Aktie aus dem 1stelligem Bereich verabschieden.
Aber nur wenn alles gut läuft.
Chance:50:50
LG
17.02.12 14:28
#825
Biggemann
Was soll denn das wieder.
ca.50%Plus vorbörslich.
Mal sehen wo das heute endet.
Mal sehen wo das heute endet.